Does UnitedHealthcare Cover Reclast (Zoledronic Acid)?

Reclast is the brand name for zoledronic acid 5 mg administered as a single yearly (or, for prevention, every-other-year) intravenous infusion. It is a bisphosphonate approved by the FDA for postmenopausal osteoporosis, osteoporosis prevention, glucocorticoid-induced osteoporosis, and Paget disease of bone. It should not be confused with Zometa, which is the same molecule sold at a higher dose and more frequent schedule for cancer-related bone disease and hypercalcemia of malignancy.

Most UnitedHealthcare commercial plans do cover Reclast, but coverage is not automatic. It generally requires prior authorization, and many formularies expect documented use of, or a documented reason to avoid, an oral bisphosphonate first. The exact tier, copay, and step-therapy rule differ by employer group, plan year, and state, and UnitedHealthcare does not publish a single universal policy that applies to every member. This article describes the general pattern reported by patients and prescribers and the FDA and CMS documents that anchor the clinical and Medicare billing framework. It cannot substitute for checking your own plan's Summary of Benefits and Coverage or calling the number on your insurance card, because the specific dollar amounts and prior-authorization forms below have not been verified against a current, plan-specific UnitedHealthcare coverage policy document.

The core, verifiable facts are these: Reclast is FDA-approved for the indications above, its label contraindicates use in patients with creatinine clearance below 35 mL/min because of acute renal impairment risk, and when it is billed as a physician-administered infusion under Medicare Part B rather than through a Part D pharmacy benefit, the beneficiary generally owes a percentage coinsurance after the deductible rather than a flat pharmacy copay. Everything beyond that (specific UHC tier placement, specific copay ranges, specific appeal turnaround times) is plan-variable and should be confirmed directly with UnitedHealthcare before a patient makes a treatment decision based on cost.

What is established versus what needs verification

Established from the FDA label: Reclast's approved indications, its once-yearly (osteoporosis treatment) or once-every-24-months (prevention) dosing, and the renal function contraindication (according to the FDA prescribing information for Reclast).

Established from CMS: Medicare Part B covers physician-administered drugs like IV zoledronic acid under a 20% coinsurance structure after the annual Part B deductible, with the allowed amount set through the average sales price mechanism (according to CMS's Medicare Part B drug average sales price pricing guidance). Exact dollar coinsurance depends on the current year's deductible and the specific allowed amount for the billing code used, both of which change annually and should be checked for the current year rather than assumed from a prior year's figures.

Plausible but plan-dependent, not independently verified here: the claim that UHC places brand Reclast at a specialty tier with a $150 to $500 copay, that step therapy requires a specific 3-month oral bisphosphonate trial, and that internal appeals resolve within 30 days. These patterns are commonly reported for specialty injectable/infusion drugs across commercial payers generally, but no UnitedHealthcare-specific formulary or medical policy document was available to confirm the exact figures for this article. Treat these as a starting expectation to verify, not a guarantee.

Not established here: any specific overturn rate for UnitedHealthcare's external independent review process for Reclast denials. A precise percentage should not be quoted to a patient without a current, sourced UHC or state insurance department report, and none was available for this draft.

Clinical trial evidence, described without a verified specific citation: Randomized trial evidence in postmenopausal women has reported that once-yearly IV zoledronic acid reduces hip and vertebral fracture risk compared with placebo, and separate randomized evidence in patients with a recent hip fracture has reported improved outcomes with zoledronic acid given after fracture repair, including a mortality signal. These are widely cited findings in osteoporosis treatment guidelines, but the specific hazard ratios and confidence intervals should be checked against the primary trial publications before being restated as precise numbers, because the citation links carried over from earlier drafts of this article could not be confirmed as pointing to the correct papers.

Prior authorization: what documentation commonly matters

Payers that require PA for zoledronic acid infusions typically want to see:

• A confirmed osteoporosis diagnosis, usually a DXA T-score at or below -2.5 at the spine, femoral neck, or total hip, or osteopenia with a documented fragility fracture
• For glucocorticoid-induced osteoporosis, documentation of a qualifying steroid dose and duration
• A prior trial of, or a documented contraindication to, an oral bisphosphonate
• Recent labs: serum calcium, 25-hydroxyvitamin D, and estimated glomerular filtration rate (eGFR), since the FDA label restricts use below a creatinine clearance threshold
• Confirmation that the patient can be adequately hydrated and does not have uncorrected hypocalcemia before infusion

Because renal function is a labeled contraindication rather than a payer preference, this documentation is worth gathering regardless of which insurer is involved.

Step therapy and when it can reasonably be contested

Payers commonly ask patients to try an oral agent (alendronate or risedronate) before approving an IV bisphosphonate, unless there is a documented reason the oral route is not appropriate. Reasons that are broadly recognized across osteoporosis treatment guidelines as grounds to skip or override step therapy include:

• Documented GI intolerance to oral bisphosphonates (esophagitis, dysphagia)
• A structural contraindication such as Barrett esophagus, esophageal stricture, or achalasia
• Inability to remain upright for 30 minutes after dosing
• Very high fracture risk, such as a recent fragility fracture, a very low T-score, or a high FRAX-estimated probability of fracture, a category that endocrine society guidelines have identified as appropriate for first-line IV bisphosphonate consideration rather than mandatory oral step therapy

If your plan denies a step-therapy override request, ask the prescriber to cite the specific guideline criterion the patient meets rather than making a general clinical-judgment argument. Specific, guideline-anchored language is what medical directors are trained to evaluate against.

Cost: what is knowable and what is not

Manufacturer list price, cash-pay averages at specific infusion centers, and specific UHC copay bands change over time and by location, so any number quoted here should be treated as illustrative rather than current. What is more durable:

• Generic zoledronic acid 5 mg/100 mL is available and is often placed at a lower cost-sharing tier than the branded product, because the active ingredient, concentration, and route of administration are identical.
• Under Medicare Part B, the beneficiary generally owes coinsurance rather than a flat copay, and the amount scales with the drug's allowed rate for that year (verify current-year figures directly with CMS or your plan).
• Manufacturer copay assistance for brand Reclast is typically restricted to commercially insured patients and cannot be combined with Medicare, Medicaid, or other federal coverage. Whether a specific patient is eligible, and the current terms, should be confirmed directly with the manufacturer's program rather than assumed.
• Site of service affects total cost. Hospital outpatient departments commonly add a facility fee on top of the drug and administration charge; independent infusion centers and some physician offices may bill only the drug and an administration code. This difference is a billing-structure pattern, not a UHC-specific rule, and it applies across most commercial and Medicare plans.

Appealing a denial

If a request is denied, UnitedHealthcare's standard structure for commercial plans includes an internal appeal process followed by the right to an external review by an independent review organization if internal appeals are unsuccessful, consistent with the appeal rights required of most commercial health plans generally. Specific deadlines (commonly measured in days from the denial notice) and turnaround times are stated on the denial letter itself and should be followed exactly, since they can vary by state and plan type. A strong appeal typically:

• States the specific denial reason and responds to each criterion individually
• Includes updated DXA results, relevant labs, and documentation of oral bisphosphonate failure or contraindication
• Cites the specific clinical guideline criterion the patient meets for step-therapy override or first-line IV therapy
• Comes from the prescriber as a letter of medical necessity, not only from the patient

Reclast UHC coverage decision framework

Use this to figure out which situation applies before contacting the plan, so the call or PA request targets the right question.

Questions worth asking your plan directly

• What formulary tier applies to zoledronic acid (brand and generic) on my specific plan this year?
• What exact step-therapy documentation satisfies the PA requirement?
• What is my specific plan's PA turnaround time and appeal deadline?
• Is my infusion site in-network, and does it bill a separate facility fee?